Komrokji R, al Ali N, Chan O, Sweet K, Kuykendall A, Lancet J, Padron E, Sallman DA. <i>IDH</i&gt; mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy. Haematologica 2023;108(4):1168-1172; https://doi.org/10.3324/haematol.2022.281607.